隐源性卒中（CS）是缺血性脑卒中的特殊类型，与卵圆孔未闭（PFO）之间的关系密切。以存在卒中风险的老年PFO群体为研究对象，通过长期随访研究，旨在明确PFO封堵术对脑血管不良事件的保护作用及临床优势，终点指标包括复发性脑卒中/复发性短暂性脑缺血，其余指标包括一般情况资料与基线临床指标。随访结果显示治疗后3 a，保守治疗组的脑血管不良事件发病率（5/21，P=0.03）显著高于PFO封堵组（1/39），Logistic分析结果显示，是否接受PFO封堵术是预测有卒中风险老年患者预后发生脑血管不良事件的唯一独立危险因素（OR=11.562，P=0.003），提示PFO封堵术可使有卒中风险的老年人群获益，与接受PFO封堵术相比，药物保守治疗组未来3 a内发生脑血管不良事件的危险是前者的11.562倍。
The number of stroke patients in China ranks first in the world. Cryptogenic stroke (CS)，a special type of ischemic stroke, is closely related to patent foramen ovale (PFO). This study focuses on the elderly PFO population at risk of stroke. Through long-term follow-up studies, the aim is to clarify the protective effect and clinical advantages of PFO closure on cerebrovascular adverse events. The endpoint indicators include recurrent stroke/recurrent transient cerebral ischemia, while the remaining indicators include general information and baseline clinical indicators. The follow-up results showed that the incidence rate of cerebrovascular adverse events in the conservative treatment group (5/21, P=0.03) was significantly higher than that in the PFO closure group (1/39) 3 years after treatment. Logistic analysis showed that whether to accept PFO closure was the only independent risk factor for predicting cerebrovascular adverse events in elderly patients with stroke risk (OR=11.562, P=0.003), suggesting that PFO closure surgery can benefit elderly individuals at risk of stroke. Compared with the group receiving PFO closure surgery, the conservative drug treatment group had an 11.562 times higher risk of developing cerebrovascular adverse events in the following 3 years.
[1] Zhou M G, Wang H D, Zeng X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2019, 394(10204): 1145-1158.
[2] Feigin V L, Forouzanfar M H, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010[J]. The Lancet, 2014, 383(9913): 245-255.
[3] Moran A, Gu D F, Zhao D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy modelChina[J]. Circulation Cardiovascular Quality and Outcomes, 2010, 3(3): 243-252.
[4] 关于印发健康中国行动——心脑血管疾病防治行动实施方案（2023—2030年）的通知[J].中华人民共和国国家卫生健康委员会公报, 2023(11): 30-33.
[5] 吴琼, 王晨冉, 赵燕, 等. 中国卒中及其亚型疾病负担和趋势研究[J]. 现代预防医学, 2021, 48(12): 2113-2119.
[6] Adams H P, Bendixen B H, Kappelle L J, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment[J]. Stroke, 1993, 24(1): 35-41.
[7] Molina C A, Santamarina E, Alvarez-Sabín J. Cryptogenic stroke, aortic arch atheroma and patent foramen ovale[J]. Cerebrovascular Diseases, 2007, 24(Suppl 1): 84-88.
[8] Lechat P, Mas J L, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke[J]. The New England Journal of Medicine, 1988, 318(18): 1148-1152.
[9] Coughlan J J, Daly A, Arnous S, et al. Patent foramen ovale and cryptogenic stroke: Contemporary evidence and treatment[J]. Expert Review of Cardiovascular Therapy, 2018, 16(1): 27-37.
[10] Alvarez C, Siddiqui W J, Aggarwal S, et al. Reduced stroke after transcatheter patent foramen ovale closure: A systematic review and meta-analysis[J]. The American Journal of the Medical Sciences, 2018, 356(2): 103-113.
[11] Stone D K, Buchwald N, Wilson C A. Updates in the management of cryptogenic stroke and patent foramen ovale[J]. Journal of Neuro-Ophthalmology, 2020, 40(1): 60-66.
[12] 中华医学会心血管内科分会, 中国医师协会心血管内科分会. 卵圆孔未闭预防性封堵术中国专家共识[J]. 中国循环杂志, 2017, 32(3): 209-214.
[13] 郭蓉, 殷丽丽, 张思艺, 等. 对比增强经颅多普勒对隐源性缺血性卒中和先兆性偏头痛患者与右向左分流不同分流量相关性的研究[J]. 中风与神经疾病杂志, 2022, 39(2): 111-114.
[14] Lee P H, Song J K, Kim J S, et al. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSEPFO trial[J]. Journal of the American College of Cardiology, 2018, 71(20): 2335-2342.
[15] 康雪, 李海洋, 孙阳阳, 等. 卵圆孔未闭合并隐源性卒中介入封堵与药物的疗效对比[J]. 第三军医大学学报, 2021, 43(22): 2468-2473.
[16] 于恺, 刘静, 陈超, 等. 介入封堵术治疗卵圆孔未闭合并偏头痛青年卒中临床疗效[J]. 临床军医杂志, 2024, 52(6): 585-588.
[17] 梁永梅, 王霄芳, 叶文倩, 等. 卵圆孔未闭封堵术对合并隐匿性脑卒中或偏头痛患者的近中期疗效观察[J]. 中国医药, 2022, 17(9): 1335-1337.
[18] Yuan K, Kasner S E. Patent foramen ovale and cryptogenic stroke: Diagnosis and updates in secondary stroke prevention[J]. Stroke and Vascular Neurology, 2018, 3(2): 84-91.
[19] Kent D M, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke[J]. Neurology, 2013, 81(7): 619-625.
[20] Mir H, Siemieniuk R A C, Ge L, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: A systematic review and network meta-analysis incorporating complementary external evidence[J]. BMJ Open, 2018, 8(7): e023761.
[21] Messé S R, Gronseth G S, Kent D M, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology[J]. Neurology, 2020, 94(20): 876-885.
[22] 张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33(1): 1-10.
